Genetic Study Finds 4 Distinct Variations of Breast Cancer

Options

Comments

  • Omaz
    Omaz Member Posts: 5,497
    edited September 2012

    Thank you for linking to this article, it looks very interesting!

  • dlb823
    dlb823 Member Posts: 9,430
    edited September 2012

    I just read that from a friend's posting on FB.  Looks like great info' -- especially on TNBC -- but I'm confused.  I thought a recent study out of the UK determined that there are 10 variants of bc.  I haven't gone back to look at that researcj, but I'm wondering if those 10 include these 4, or how the 4 and 10 relate to each other.  Does anyone know?     Deanna

  • comingtoterms
    comingtoterms Member Posts: 421
    edited September 2012

    What I think is sad is how, for those of us diagnosed years ago, we can't get this information about our tumor because it's long gone! Then again, if we 'turned over' our tumors to a local research facility, does that mean they could still screen for new research info from it? Tammy

  • fredntan
    fredntan Member Posts: 1,821
    edited September 2012

    terms-your slides are at the hosp that did your mastectomy. I don't think they throw those away.

  • dogsandjogs
    dogsandjogs Member Posts: 1,907
    edited September 2012

    Would the hospital still have my slides from 30 years ago?

  • Blessings2011
    Blessings2011 Member Posts: 4,276
    edited September 2012

    I always thought I'd like to know more about the kind of BC my mom was dx'd with at the age of 61 in 1983!

    She had a radical mastectomy and no other treatment. Of course, no other testing was available back then.

    I was 61 when I was dx'd in 2011.

  • cp418
    cp418 Member Posts: 7,079
    edited September 2012

    New Breast Cancer Study May Alter Approach To Treatments.

    There was a significant amount of media coverage of a new study on breast cancer published online Sunday in the journal Nature. Much of the reporting focused on how the findings are significantly altering the scientific understanding of breast cancer, and will likely impact the type of treatments that patients receive.

            In a front-page story, the New York Times (9/24, A1, Kolata, Subscription Publication) reports that "researchers have identified four genetically distinct types of the cancer," and "within those types, they found hallmark genetic changes that are driving many cancers." These findings "are expected to lead to new treatments" with medication "already approved for cancers in other parts of the body and new ideas for more precise treatments aimed at genetic aberrations that now have no known treatment." Dr. Matthew Ellis, a researcher for the study, said "this is the road map for how we might cure breast cancer in the future."

            The AP (9/24) reports that "the new finding offers hints that one type of breast cancer might be vulnerable" to medications "that already work against ovarian cancer." According to the AP, the study "is the latest example of research into the biological details of tumors, rather than focusing primarily on where cancer arises in the body." The article adds that "the hope is that such research can reveal cancer's genetic weaknesses for better drug targeting."

            Similarly, NBC Nightly News (9/23, story 7, 1:20, Holt) broadcast, "the research opens the possibility of trying" different medications, "including some already on the market to treat other forms of cancer, and the new genetic information will give" pharmaceutical companies "clues for developing new" treatments. It adds, "Of course, everything will have to be tested in years of clinical trials. But the new information provides a wealth of new leads to treat a disease that still kills 35,000 women a year in this country."

            The San Francisco Chronicle (9/24, Colliver) reports that this "is the fifth study to come out of the Cancer Genome Atlas, a project funded by the National Institutes of Health to examine the key genomic changes in at least 20 different cancer types." According to the article, "the project's researchers have previously published reports on glioblastoma, an aggressive type of brain cancer and on a form of ovarian cancer as well as colon cancer and, earlier this month, squamous cell lung cancer."

            USA Today (9/24, Szabo) notes that in this study, scientists "analyzed tissue from 348 breast cancers, finding that most tumors are caused by mutations in 30 to 50 genes."

            HealthDay (9/24, Preidt) adds that the scientists "used six different technologies" to analyze the tumors, looking for "defects in DNA, RNA and proteins." The study team "confirmed the existence of four main subtypes of breast cancer -- luminol A, luminal B, HER2 and basal-like -- and found unique genetic and molecular signatures within each of the subtypes."

    --------------------------------------

    Researchers and patient advocates caution that it will still take years to translate the new insights into transformative new treatments. Even within the four major types of breast cancer, individual tumors appear to be driven by their own sets of genetic changes. A wide variety of drugs will most likely need to be developed to tailor medicines to individual tumors.

  • gpawelski
    gpawelski Member Posts: 564
    edited September 2012

    People will think because they are being completely genotyped, this will give all the answers needed. But it won't. Genotyping will only be of value for drugs for which a gene mutation is informative -- basically KRAS and EGFR mutations -- and we already have tests for those and they are of very limited value. Otherwise, it's a ton of information for which the drug selection value is pretty darn useless.

    What's more important than what genes are in the DNA is what genes are actively making RNA, which RNA is actively making protein, which protein is being turned off or turned on, and how all of the proteins in the cell are interacting with each other. The only way to get the latter information, which is ultimately what you want, is to treat the patient with phenotype analysis. In drug selection, phenotype analysis doesn't dismiss DNA testing, it uses all the information, measuring the interaction of the entire genome, to design the best treatment for each individual.

Categories